Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis

Christof Geldmacher\textsuperscript{a,b}, Alimuddin Zumla\textsuperscript{c}, and Michael Hoelscher\textsuperscript{a,b}

**Purpose of review**
HIV infection is the main driver of the HIV/tuberculosis (TB) syndemic in southern Africa since the early 1990s, when HIV infection rates started to increase exponentially and TB incidence rates quadrupled simultaneously. Here, we discuss pathogenic mechanisms of HIV-induced CD4 T-cell depletion and their potential impact on immune control of Mycobacterium tuberculosis.

**Recent findings**
Depletion of effector memory CD4 T cells from the air–tissue interphase, their dysfunctional regeneration and the preferential depletion of MTB-specific CD4 T cells from circulation and from the air–tissue interphase might be key factors for the increased susceptibility to develop active TB after HIV infection.

**Summary**
Early initiation of antiretroviral therapy or the development of an efficacious HIV vaccine would be the best options to reduce morbidity and mortality associated with the HIV/TB syndemic.

**Keywords**
CD4 T cell, HIV, tuberculosis

**INTRODUCTION**

Originating from multiple zoonotic transmissions of simian immunodeficiency virus (SIV) to humans in west and central Africa, HIV-1 started to spread in the early 1900s into larger populations. The most successful branch of HIV, group M was transmitted from the chimpanzee Pan troglodytes troglodytes in which it is endemic [1]. Initially, the spread of HIV-1 group M was geographically confined to western–central Africa, but international migration and travel enabled a successful spread across the world in the second half of the 20th century. Since its discovery, as the causative agent of the AIDS in 1983 [2,3], HIV prevalence rates have increased steadily on a global scale to 33 million infected patients – 0.8% of the adult population – in 2009 [4]. The most dramatic increase in HIV prevalence rates was observed in sub-Saharan African countries and an estimated 68% of globally HIV-infected people live in sub-Saharan Africa. Particularly, South African countries are at the ‘epicenter’ of the HIV epidemic, with adult prevalence rates of up to 25% population [4].

Globally, active tuberculosis (TB) remains among the leading causes of death from an infectious agent. In 2010, the estimated global TB incidence rate was 128 cases per 100 000 population, which equates to 8.8 million (range, 8.5–9.2 million) incident TB cases [5]. Since the 1990s, the worldwide TB incidences have developed quite divergently. Whereas in most parts of the world TB incidence rates remained stable or declined, African incidence rates increased by almost 30%. This increase was most pronounced in Southern Africa, especially South Africa where the incidence nearly quadrupled to 981 cases per 100 000 population (95% uncertainty interval 806–1170). HIV/TB coinfection numbers (Fig. 1; red line) indicate that in these countries a large proportion of the TB incidence is related to
immunodeficiency caused by HIV infection. In South Africa, approximately 60% of TB incident cases are HIV infected and in total the African region accounts for 82% of TB cases among people living with HIV [5]. The dramatic mortality of this co-epidemic in Southern Africa is highlighted by a recent postmortem study of young inpatients (18–45 years) of a hospital in KwaZulu-Natal that found that 94% were HIV+ and 69% of them had active TB or were currently on TB treatment at the time of death [6].

The HIV-related factors that contribute to the increased prevalence of active TB in HIV high-endemic areas are obvious. An impaired immune system will change the acquisition rate of infection following exposure. Similarly will the loss of immune control influence the rate of recurrence of subclinically infected individuals. The proportional contribution of these factors is unclear and subject of an ongoing debate [7]. There are data from cohorts that indicate a two-fold to three-fold increase of active TB disease within the first year after HIV seroconversion and that is not a direct function of the depletion of the blood CD4 cells [8,9]. In a macaque model for HIV-induced TB reactivation, eight of eight macaques, who were latently infected with MTB, reactivated within less than a year after infection with a high dose of SIV [10**].

Here, we discuss how the depletion of memory CD4 T cells and MTB-specific CD4 T cells after HIV infection could contribute to loss of MTB immune control.

### IMMUNITY TO MYCOBACTERIUM TUBERCULOSIS INFECTION

Infection with MTB is caused by aerosolic transmission and primarily targets the respiratory system. Immune correlates of protection are best defined in the murine model. Although not reflecting all aspects of human TB pathogenesis, it serves as a good animal model to elucidate fundamental questions of host–pathogen interaction and immunity [11,12]; upon inhalation, MTB is phagocytosed by alveolar macrophages and myloid dendritic cells (mDCs) [13]. MTB is adapted to survive and replicate intracellularly within the macrophage phagosome.
MTB-infected myloid dendritic cells, which actively sample the mucosal environment, migrate to the draining, lymph nodes to support initiation of the MTB-specific adaptive immune responses [13,14]; a delay in priming the adaptive immune response is thought to be critical in establishing bacterial persistence [14,15]. Initial priming of the adaptive immune response triggers expansion and phenotypic and functional maturation of MTB-specific T cells, which recirculate and home to the primary site of infection, in which they activate infected macrophages through the secretion of interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) [16**,17]. These Th1 cytokines are important mediators for arresting intraendosomal MTB growth, for microbial killing and, perhaps most importantly, for granuloma formation and maturation [12,18]. In addition, IFN-γ/TNF-independent T-cell-mediated effector mechanisms also contribute to the control of MTB [16**,19]. The TB granuloma is the hallmark of the MTB-specific immune response and locally restricts mycobacterial spread both in humans and in mice [12,20]. Murine studies using advanced dynamic imaging methodology have shown a surprisingly mobile CD4 T-cell population during early granuloma formation and only low frequencies of IFN-γ secreting mycobacteria-specific CD4 T cells (5–8%) at a given time point [16**,21]. Indeed, during these early stages of granuloma formation, the T cells surrounding the mycobacteria are somehow reminiscent of riot police kettling tactics to contain street protests.

MTB-specific CD4 T-cell responses play a central role in the control of aerosolic MTB infection [15,17,22,23]; Antibody-mediated depletion of CD4 T cells but not CD8 T cells, slightly reminiscent of HIV pathogenesis, drastically reduces control of MTB growth and survival upon challenge of mice [24]. Perhaps most conclusive, adoptive transfer of transgenic MTB-specific CD4 Th 1 cells potently restricts MTB growth in the lungs of recipient mice in a dose-dependent manner [17]. Thus, although CD4 T-cell independent mechanisms are likely to contribute to microbial immunity, CD4 T cells are key in the control of murine MTB infection.

Protective immunity against human TB remains poorly characterized. Human genetic mutations in IL-12p40 or IFN-γ receptor genes [25] or treatment with TNF antagonists [26] are associated with a greater risk of TB disease progression, consistent with a central role of 'TH1 cytokines' for efficient control of MTB infection also in humans. Nonhuman primate experiments not only support an important role for CD4 T cells [10**,27] but also suggest a more prominent role for CD8 T cells, which include nonclassical CD8 T cells found in humans, but not in mice [28]. Thus, impaired control of MTB infection after HIV infection still provides the best evidence for an important role of CD4 T cells in human anti-MTB immunity.

**AIDS VIRUS-INDUCED DEPLETION OF CD4 T CELLS FROM THE AIR–TISSUE INTERPHASE IN THE LUNG**

Loss of CD4 T cells during HIV disease progression is brought on by persistent viral replication. Interfering with viral replication by highly active antiretroviral therapy (HAART) initiation reconstitutes CD4 T-cell counts, largely restores pathogen-specific CD4 T-cell responses and substantially decreases the risk of developing active TB [29–31]. CCR5-tropic virus variants are responsible for most transmission events and typically prevail until late phase of infection [32]. During natural HIV infection, IFN-γ tropism evolves only relatively late in infection after CD4 T-cell numbers have dropped substantially [33] and is associated with infection and depletion of naive CD4 T cells [34]. Thus, early loss of MTB immune control should usually be linked to CCR5 tropism and selective targeting CCR5+ CD4 T cells; CCR5 expression is characteristic of effector memory CD4 T cells isolated from mucosal tissues including the lung [35–37] and can be induced by antigenic stimulation and activation of CD4 T cells in vitro [38], but is largely absent from naive CD4 T cells. CCR5-tropic viruses preferentially infect and replicate in activated memory CD4 T cells that express the chemokine receptor CCR5 and these cells are preferentially depleted after AIDS virus infection [35]. Pathogenesis of CCR5-tropic virus infection has been intensively studied after experimental infection of simian rhesus macaques with SIVs — a good model for human HIV infection. Both, acute and chronic SIV and HIV infection results in extensive depletion of effector memory CD4 T cells from mucosal effector sites, [39–42] including the tissue–air interphase of the lung [36,43]. Hence, effector memory CD4 T cells at the primary site of aerosolic MTB infection, are also a primary target for depletion after infection with CCR5 tropic viruses and the timing of their depletion after SIV infection is associated with reactivation of MTB infection in macaques [10**]. Influx of newly generated CD4 T effector memory cells can partially replenish CD4 T cells in the air–tissue interphase, despite their reduced life span during SIV infection [36,43,44]. Increased cellular turn over and maturation of central memory into effector memory CD4 T cells are responsible for continuous renewal of this
Effect of memory T-cell population and probably simultaneously promote HIV virus replication in transitional CD4 T cells [45,46], resulting in a net loss of effector memory CD4 T-cell output from secondary lymphoid organs. Progressive loss of the capacity for renewal of this effector memory CD4 T-cell pool is thought to be central to the pathogenesis AIDS virus infection [43]. Substantial and progressive depletion of CD4 T cell within tissue–air interphase is also characteristic of chronic HIV-infected humans [47**,48**,49*]. Human tissue–air interphase CD4 T cells are effector memory T cells as characterized by a CD45RA−CCR7−CD27− phenotype [47**,48**]. Blocking virus replication by HAART initiation reverses CD4 T-cell depletion within tissue–air interphase [49*] and reduces the risk of developing active TB by at least 70% [29]. Together, these data demonstrate that the site of primary MTB infection is particularly vulnerable to AIDS virus-induced immune defects.

The timing of effector memory CD4 T-cell depletion from the air–tissue interphase after SIV infection is associated with reactivation of MTB infection [10**], suggesting that HIV infection can reduce efficacy of the protective properties of an existing granuloma [50*]. This finding is supported by histological studies that found differences in the cellular composition, architecture and function of MTB granulomas associated with HIV infection, such as fewer mononuclear cells, fewer CD4 T cell [51,52], perturbations in TNF expression and larger areas of necrosis [51,53]. A more recent study found no such morphological alterations in granulomas during pleural TB during earlier HIV disease stages [53]. Interestingly, granulocyte involvement appears to be increased granulomas from HIV+ patients, resembling a pattern also observed in MTB-infected CD4 knockout mice [11,23,51]. In summary, relatively little information is known about HIV interference with the MTB granuloma. The pathogenic mechanisms of AIDS virus-induced granuloma dysfunction need further clarification.

**DYNAMICS OF MYCOBACTERIUM TUBERCULOSIS-SPECIFIC CD4 TH1-CELL RESPONSES AFTER HIV INFECTION**

The timing of disease caused by opportunistic infections is not strictly related to the extent of CD4 T-cell depletion for a given pathogen. HIV-associated changes in the quantity or quality of opportunistic pathogen-specific CD4 T-cell responses could potentially contribute to increased susceptibility to a given pathogen [54]. For example, clinical complications caused by cytomegalovirus (CMV) closely correlates with depletion of CMV-specific CD4 T-cell responses [55–57]. Similarly, in SIV/bacillus Calmette-Guérin coinfected rhesus macaques reactivation of tuberculosis-like disease coincides with waning mycobacterial-specific T-cell proliferative responses [27]. Several studies, including our own, have recently shown that MTB-specific CD4 T-cell responses are preferentially depleted after HIV infection from circulation and also from the tissue–air interphase [47**,48**,58*] suggesting that MTB-specific immunity is particularly vulnerable to HIV-induced defects. These data support the hypothesis that a reduction in the generation of lung homing MTB-specific effector memory CD4 Th1 cells after HIV infection is a key factor in the increase risk for development of active TB (Fig. 2).

The reasons for differential depletion of different pathogen-specific CD4 T cells after HIV infection are probably multifactorial. Phenotypic and functional properties of MTB-specific CD4 T cells, such as surface expression of CCR5 [59], a low capacity to secrete ‘protective’ CCR5 ligand MIP-1β and large capacity for interleukin (IL) 2-dependent T-cell proliferation promote cellular HIV infection in vitro and in vivo [58*,59–61]. And indeed, MTB-specific CD4 T cells have significantly higher cell-associated viral loads in vivo as compared with total memory CD4 T cells during active TB [58*]. Activated mycobacteria-specific CD4 T-cell responses strongly promote HIV replication both *in vitro* [60] and *in vivo* [62,63]. These data support a model in which a combination of proinflammatory cytokines and cell-contact dependent costimulatory interactions maximize transcription of the HIV genome and production of virions in HIV-infected antigen-presenting cells, which transmit to responding CCR5+, proliferating MTB-specific CD4 T cells [64,65] Refer to Fig. 4/2. Such a scenario would depend on ongoing MTB-specific stimulation of CD4 T cells during latency. A continuous crosstalk between the host immune system and the persisting pathogens [66] would support such a model.

However, the level of antigenic stimulation during MTB latency is unclear and probably varies between individuals. Loss of MTB-specific CD4 T-cell responses rather argues against strong antigenic stimulation after HIV infection, because, somehow counterintuitive, MTB-specific CD4 T cells can often be detected in HIV-positive patients with active TB, most probable due to antigen-driven CD4 T-cell expansion counteracting (or concealing) depletion. Persistent or expanding MTB responses after HIV and SIV infection have indeed rather been associated with subsequent progression [59,67,68]. As a consequence, it is difficult to dissect the effects of AIDS virus-associated CD4 T-cell depletion in the presence of strong antigen-driven cellular CD4 T-cell...
Co-infection of poverty related diseases with worms

**FIGURE 2.** Proposed mechanism of how HIV-induced CD4 T-cell depletion impairs immune control of MTB infection. 1. Infection of airways with MTB (red rods); the bacilli are taken up by alveolar macrophages (pale orange) and dendritic cells (DCs, dark orange). MTB-infected DCs then migrate to the thoracic lymph nodes to trigger the adaptive MTB-specific CD4 T-cell response. Some MTB-infected DCs are coinfected with HIV. 2. Within the lymph node, HIV is efficiently transferred from DCs to MTB-specific CD4 T cells that respond to cognate antigen. DC–T-cell interaction maximizes HIV virion production in antigen-presenting cells and simultaneously increases CCR5 expression by activated MTB-specific CD4 T cells (pink). IL-2-dependent cell cycling promotes complete reverse transcription of the viral RNA genome and as a consequence productive...
expansion during reactivating TB. In the majority of 'latently' infected humans, T-cell stimulation apparently is insufficient to maintain MTB-specific CD4 T-cell responses after HIV infection, implying that other protective mechanisms, such as ‘hermetically sealed granulomas’ or other immune cell subsets [28] might contain MTB replication. Alternatively, the presence of MTB-specific T-cell memory might not necessarily equate with reactivatable disease [29,69,70]. Epidemiological studies are divided: some studies argue rather for novo exposure as compared with reactivation as a frequent cause of HIV-associated active TB in high-burden settings of sub-Saharan Africa [7], whereas a recent study shows a five-fold increased TB incidence of HIV+/interferon gamma release assay positive (IGRA+) patients (5%) compared with HIV+/IGRA− patients (<1%), supporting latent MTB reactivation as an important cause for active TB in HIV patients [71]. Thus, both mechanisms are likely to play a role. However, it is tempting to speculate that recent exposure and early granuloma formation and maturation is more likely to be affected by HIV interference, as compared with old, mature, ‘fibrotic and calcified’ lesions, which might restrict bacterial dissemination more independent of T-cell effector function.

CONCLUSION

In conclusion, AIDS virus infection interferes with the generation of effector memory CD4 T cell that migrate to the primary site of MTB infection – the lung – and dramatically increases risk of developing active TB. Moreover, MTB-specific CD4 T-cell responses are selectively depleted both, in circulation and at the air–tissue interphase of the lung, and probably further aggravating the failure of the immune system to efficiently control MTB after HIV infection. Other ‘more global’ immune defects brought on by persistent viral replication, such as persistent immune activation or dysfunction and depletion of antigen-presenting cells, are also likely to promote TB disease progression in HIV-infected individuals. Hence, at this point in time, early initiation of antiretroviral therapy or the development of an efficacious HIV vaccine would be the best options to reduce morbidity and mortality associated with this co-epidemic.

Acknowledgements

We would like to thank Jennifer Ring for her wonderful illustration of Fig. 2.

Conflicts of interest

We have no conflicts of interest to report.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 287–289).

1. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006; 313:523–526.
2. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868–871.
3. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytotoxic lymphocytes (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984; 224:500–503.
4. UNAIDS. Epidemiologic update 2010. http://www.unaids.org/globalreport. [Accessed 22 November 2011].
5. WHO. Global tuberculosis control 2011. http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf. [Accessed 22 November 2011].
6. Cohen T, Murray M, Wallengren K, et al. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study. PLoS Med 2010; 7:e1000296.
7. Houben RM, Crampin AC, Ndhlouv R, et al. Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection. Int J Tuberc Lung Dis 2011; 15:24–31.
8. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191:150–158.
9. Glynn JR, Murray J, Bester A, et al. Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. AIDS 2008; 22:1859–1867.
10. Diedrich CR, Mattila JT, Klein E, et al. Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One 2010; 5:e9611. This article studies reactivation dynamics of MTB infection in macaques with latent (or clinical quiescent) MTB infection after challenge with pathogenic CCR5-tropic simian immunodeficiency virus. Particularly monkeys with profound CD4 T-cell depletion in bronchoalveolar lavage and in the peripheral blood progress to active TB very rapidly.
Co-infection of poverty related diseases with worms

11. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27:393–422.
12. Reece ST, Kaufmann SH. Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis? Curr Opin Microbiol 2012; 15:63–70.
13. Wolf AJ, Linas B, Treweeje-Czujaz GJ, et al. Mycobacterium tuberculosis infection induces dendritic cells with high frequency and impairs their function in vitro. J Immunol 2007; 179:2509–2519.
14. Reiley WW, Calayag MD, Wittmer ST, Levy JA. HIV pathogenesis: 25 years of progress and persistent challenges. J Infect Dis 2006; 194:1093–1097.
15. Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434:1148–1152.
16. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200:761–770.
17. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749–769.
18. Okoye A, Meier-Schellenberg M, Brenchley JM, et al. Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med 2007; 204:2171–2185.
19. Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 2006; 18:399–405.
20. Ganese A, Chattopadhay PK, Brodie TM, et al. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis 2010; 201:272–284.
21. Biancotto A, Iglehart SJ, Vanpouille C, et al. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 2001; 165:5407–5416.
22. Saunders BM, Frank AA, Orme IM, Cooper AM. CD4+ T cell depletion is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 2002; 216:65–72.
23. Moogas T, Goodrich ME, Ryan L, et al. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2001; 193:271–280.
24. Shen JY, Barnes PF, Rea TH, Meyer PR. Immunohistology of tuberculous lymphadenitis in HIV-infected individuals. J Clin Pathol 1999; 52:1403–14033.
25. Gallegos AM, Palmer EG, Glickman MS. Delayed protection by ESAT-6-specific CD4+ T cells after airborne M. tuberculosis infection using intranasal microbicide combined with adoptive transfer of fluorescent MTB-specific transgenic CD4+ T cells.
26. Gallegos AM, Palmer EG, Glickman MS. Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection. J Exp Med 2008; 205:2359–2368.
27. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the granulocyte immune response against Mycobacterium tuberculosis in mice. Immunology 1995; 95:2561–572.
28. Gallegos AM, van Heijst JW, Samstein M, et al. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog 2011; 7:e1002052.
29. Huyhn KK, Joshi SA, Brown EJ. A delicate dance: host response to mycobacterial infection. Curr Opin Immunol 2011; 23:484–477.
30. Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiency virus type 1 infection impairs the bronchoalveolar lavage CD4 T-cell responses targeting various respiratory pathogens including MTB.
31. Kaldor B, Ribins RJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar lavage CD4 T-cell responses. PLoS Med 2008; 5:271–284.
32. Caruso AM, Serbina N, Klein E, et al. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 1999; 162:5407–5416.
33. Sauders BM, Frank AA, Orme IM, Cooper AM. CD4+ T cell depletion is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 2002; 216:65–72.
34. Moogas T, Goodrich ME, Ryan L, et al. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2001; 193:271–280.
35. Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiency virus type 1 infection impairs the bronchoalveolar lavage CD4 T-cell responses targeting various respiratory pathogens including MTB.
36. Kaldor B, Ribins RJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar lavage CD4 T-cell responses to aerosol Mycobacterium tuberculosis infection in a murine M. tuberculosis infection model using intranasal microbicide combined with adoptive transfer of fluorescent MTB-specific transgenic CD4+ T cells.
37. Gallegos AM, Palmer EG, Glickman MS. Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection. J Exp Med 2008; 205:2359–2368.
38. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the granulocyte immune response against Mycobacterium tuberculosis in mice. Immunology 1995; 95:2561–572.
39. Gallegos AM, van Heijst JW, Samstein M, et al. A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo. PLoS Pathog 2011; 7:e1002052.
40. Huyhn KK, Joshi SA, Brown EJ. A delicate dance: host response to mycobacterial infection. Curr Opin Immunol 2011; 23:484–477.
41. Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiency virus type 1 infection impairs the bronchoalveolar lavage CD4 T-cell responses. PLoS Med 2008; 5:271–284.
42. Caruso AM, Serbina N, Klein E, et al. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 1999; 162:5407–5416.
43. Sauders BM, Frank AA, Orme IM, Cooper AM. CD4+ T cell depletion is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 2002; 216:65–72.
44. Moogas T, Goodrich ME, Ryan L, et al. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2001; 193:271–280.
45. Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiency virus type 1 infection impairs the bronchoalveolar lavage CD4 T-cell responses targeting various respiratory pathogens including MTB.
46. Kaldor B, Ribins RJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar lavage CD4 T-cell responses. PLoS Med 2008; 5:271–284.
47. Caruso AM, Serbina N, Klein E, et al. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 1999; 162:5407–5416.
48. Sauders BM, Frank AA, Orme IM, Cooper AM. CD4+ T cell depletion is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 2002; 216:65–72.
49. Moogas T, Goodrich ME, Ryan L, et al. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med 2001; 193:271–280.
50. Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiency virus type 1 infection impairs the bronchoalveolar lavage CD4 T-cell responses targeting various respiratory pathogens including MTB.
51. Kaldor B, Ribins RJ, Wood K, et al. HIV-1 infection impairs the bronchoalveolar lavage CD4 T-cell responses to aerosol Mycobacterium tuberculosis infection in a murine M. tuberculosis infection model using intranasal microbicide combined with adoptive transfer of fluorescent MTB-specific transgenic CD4+ T cells.
59. Geldmacher C, Schuetz A, Ngwenyama N, et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008; 198:1590–1598.
60. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157:1271–1278.
61. Finberg RW, Wahl SM, Allen JB, et al. Selective elimination of HIV-1-infected cells with an interleukin-2 receptor-specific cytotoxin. Science 1991; 252:1703–1705.
62. Cheynier R, Gratton S, Halloran M, et al. Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination. Nat Med 1998; 4:421–427.
63. Nakata K, Rom WN, Honda Y, et al. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 1997; 155:996–1003.
64. Hoshino Y, Nakata K, Hoshino S, et al. Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J Exp Med 2002; 195:495–505.
65. Lore K, Smed-Sorensen A, Vasudevan J, et al. Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med 2005; 201:2023–2033.
66. Ulrichs T, Kosmiadi GA, Jorg S, et al. Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma. J Infect Dis 2005; 192:99–97.
67. Schuetz A, Haule A, Reither K, et al. Monitoring CD27 expression to evaluate Mycobacterium tuberculosis activity in HIV-1 infected individuals in vivo. PloS One 2011; 6:e27284.
68. Mattila JT, Diedrich CR, Lin PL, et al. Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation. J Immunol 2011; 186:3527–3537.
69. Ehlers S. Lazy dynamic or minimally recrudescent? On the elusive nature and location of the mycobacterium responsible for latent tuberculosis. Infection 2009; 37:87–95.
70. Barry CE 3rd, Bosshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7:845–855.
71. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377:1588–1598.